KYMERA THERAPEUTICS, INC. (KYMR) Current Ratio
- Current ratio · latest quarter: Value 10.34×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 10.34× | Current assets / current liabilities. $737.26M ÷ $71.33M ≈ 10.34× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 737.26M USD | Assets, Current |
| Current obligations | 71.33M USD | Liabilities, Current |
| Cash and equivalents | 124.48M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 566.51M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 20.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 8.92M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $737.26M | $71.33M | $124.48M | $566.51M | $20.00M | (m) | $8.92M | (m) | 10.34× |
| 2026-03-31 | $677.43M | $62.64M | $144.09M | $506.84M | (m) | (m) | $12.84M | (m) | 10.81× |
| 2025-12-31 | $871.21M | $83.21M | $357.01M | $491.26M | $0.00 | (m) | $4.01M | (m) | 10.47× |
| 2025-09-30 | $528.30M | $71.58M | $112.95M | $392.73M | (m) | (m) | $5.51M | (m) | 7.38× |
| 2025-06-30 | $728.33M | $87.54M | $335.82M | $329.63M | $40.00M | (m) | $5.78M | (m) | 8.32× |
| 2025-03-31 | $500.95M | $58.99M | $89.97M | $373.18M | (m) | (m) | $10.26M | (m) | 8.49× |
| 2024-12-31 | $510.27M | $67.77M | $120.26M | $368.49M | (m) | (m) | $5.99M | (m) | 7.53× |
| 2024-09-30 | $568.72M | $66.53M | $110.72M | $439.25M | $0.00 | (m) | $6.49M | (m) | 8.55× |
| 2024-06-30 | $525.41M | $62.14M | $67.61M | $442.34M | $0.00 | (m) | $6.51M | (m) | 8.45× |
| 2024-03-31 | $537.25M | $56.14M | $93.51M | $427.03M | $0.00 | (m) | $6.81M | (m) | 9.57× |
| 2023-12-31 | $405.32M | $85.69M | $109.97M | $264.92M | $15.00M | (m) | $7.08M | (m) | 4.73× |
| 2023-09-30 | $375.69M | $63.17M | $81.05M | $276.77M | (m) | (m) | $4.98M | (m) | 5.95× |
| 2023-06-30 | $385.40M | $54.60M | $52.39M | $315.19M | (m) | (m) | $3.75M | (m) | 7.06× |
| 2023-03-31 | $411.55M | $61.93M | $50.15M | $346.73M | (m) | (m) | $6.48M | (m) | 6.65× |
| 2022-12-31 | $419.42M | $71.34M | $68.39M | $338.77M | $0.00 | (m) | $4.33M | (m) | 5.88× |
| 2022-09-30 | $494.02M | $91.12M | $155.66M | $326.25M | (m) | (m) | $6.33M | (m) | 5.42× |
| 2022-06-30 | $402.77M | $87.50M | $76.91M | $315.39M | (m) | (m) | $2.37M | (m) | 4.60× |
| 2022-03-31 | $431.38M | $88.34M | $33.73M | $387.08M | (m) | (m) | $2.57M | (m) | 4.88× |
| 2021-12-31 | $451.27M | $92.54M | $47.98M | $394.44M | (m) | (m) | $4.00M | (m) | 4.88× |
| 2021-09-30 | $543.73M | $94.49M | $156.82M | $379.57M | (m) | (m) | $5.03M | (m) | 5.75× |
| 2021-06-30 | $364.81M | $108.69M | $84.90M | $274.20M | (m) | (m) | $8.18M | (m) | 3.36× |
| 2021-03-31 | $340.79M | $110.14M | $53.10M | $280.44M | (m) | (m) | $8.35M | (m) | 3.09× |
| 2020-12-31 | $302.34M | $110.62M | $31.00M | $265.20M | (m) | (m) | $4.37M | (m) | 2.73× |
| 2020-09-30 | $297.36M | $107.29M | $54.59M | $239.25M | (m) | (m) | $3.98M | (m) | 2.77× |
| 2019-12-31 | $92.84M | $34.57M | $76.02M | $15.94M | (m) | (m) | $3.28M | (m) | 2.69× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |